WEKO3
アイテム
{"_buckets": {"deposit": "539c321c-4576-4f62-8c4c-1b0c7fb19eb0"}, "_deposit": {"created_by": 2, "id": "12259", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "12259"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00012259", "sets": ["30"]}, "author_link": ["45769", "45770"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2011-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "98", "bibliographicPageStart": "87", "bibliographicVolumeNumber": "9", "bibliographic_titles": [{"bibliographic_title": "Current Vascular Pharmacology"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Hypercholesterolemia is a major risk factor for cardiovascular diseases that has been managed mostly with 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors (statins) that suppress de novo cholesterol synthesis in the liver. Statins also have beneficial pleiotropic effects on the atherosclerotic process that are independent of their ability to lower lipid values. However, the levels of low-density lipoprotein cholesterol (LDL-C) in most hypercholesterolemic patients at high risk for cardiovascular disease do not reach the goals proposed by guidelines even when prescribed with statins. Ezetimibe is a new lipid-lowering agent that blocks the intestinal absorption of dietary and biliary cholesterol and reduces LDL-C levels, especially when combined with statins. However, its effect on cardiovascular events remains unknown. We reviewed the effects of ezetimibe on cardiovascular diseases, in particular, vascular endothelial function, which is initially impaired during the atherogenetic process and is an important predictor of cardiovascular events. The simultaneous inhibition of cholesterol synthesis by statin and of cholesterol absorption by ezetimibe might retard the atherogenetic process. These effects are considered to be mainly mediated by lipid lowering. However, further studies should elucidate the mechanism of the anti-atherosclerotic effects induced by ezetimibe; for instance, whether or not it directly affects atherogenesis independently from its lipid-lowering effects.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Current Vascular Pharmacology, 9(1), pp.87-98; 2011", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Bentham Science Publishers"}]}, "item_2_relation_11": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "21044017", "subitem_relation_type_select": "PMID"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2011 Bentham Science Publishers Ltd."}]}, "item_2_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA11851661", "subitem_source_identifier_type": "NCID"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "15701611", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "18756212", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ikeda, Satoshi"}], "nameIdentifiers": [{"nameIdentifier": "45769", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Maemura, Koji"}], "nameIdentifiers": [{"nameIdentifier": "45770", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "CVP9_87.pdf", "filesize": [{"value": "283.0 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 283000.0, "url": {"label": "CVP9_87.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/12259/files/CVP9_87.pdf"}, "version_id": "65186d9c-4f6b-4a48-a2ec-adf6849d82d6"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Atherosclerosis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "C-reactive protein", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Cardiovascular disease", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Nitric oxide", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Oxidative stress", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Ezetimibe and vascular endothelial function.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Ezetimibe and vascular endothelial function."}]}, "item_type_id": "2", "owner": "2", "path": ["30"], "permalink_uri": "http://hdl.handle.net/10069/26388", "pubdate": {"attribute_name": "公開日", "attribute_value": "2011-11-15"}, "publish_date": "2011-11-15", "publish_status": "0", "recid": "12259", "relation": {}, "relation_version_is_last": true, "title": ["Ezetimibe and vascular endothelial function."], "weko_shared_id": -1}
Ezetimibe and vascular endothelial function.
http://hdl.handle.net/10069/26388
http://hdl.handle.net/10069/263885425f3cd-3582-4537-933c-7c497fd3881d
名前 / ファイル | ライセンス | アクション |
---|---|---|
CVP9_87.pdf (283.0 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2011-11-15 | |||||
タイトル | ||||||
タイトル | Ezetimibe and vascular endothelial function. | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Atherosclerosis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | C-reactive protein | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Cardiovascular disease | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Nitric oxide | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Oxidative stress | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Ikeda, Satoshi
× Ikeda, Satoshi× Maemura, Koji |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Hypercholesterolemia is a major risk factor for cardiovascular diseases that has been managed mostly with 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors (statins) that suppress de novo cholesterol synthesis in the liver. Statins also have beneficial pleiotropic effects on the atherosclerotic process that are independent of their ability to lower lipid values. However, the levels of low-density lipoprotein cholesterol (LDL-C) in most hypercholesterolemic patients at high risk for cardiovascular disease do not reach the goals proposed by guidelines even when prescribed with statins. Ezetimibe is a new lipid-lowering agent that blocks the intestinal absorption of dietary and biliary cholesterol and reduces LDL-C levels, especially when combined with statins. However, its effect on cardiovascular events remains unknown. We reviewed the effects of ezetimibe on cardiovascular diseases, in particular, vascular endothelial function, which is initially impaired during the atherogenetic process and is an important predictor of cardiovascular events. The simultaneous inhibition of cholesterol synthesis by statin and of cholesterol absorption by ezetimibe might retard the atherogenetic process. These effects are considered to be mainly mediated by lipid lowering. However, further studies should elucidate the mechanism of the anti-atherosclerotic effects induced by ezetimibe; for instance, whether or not it directly affects atherogenesis independently from its lipid-lowering effects. | |||||
書誌情報 |
Current Vascular Pharmacology 巻 9, 号 1, p. 87-98, 発行日 2011-01 |
|||||
出版者 | ||||||
出版者 | Bentham Science Publishers | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 15701611 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 18756212 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA11851661 | |||||
PubMed番号 | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | PMID | |||||
関連識別子 | 21044017 | |||||
権利 | ||||||
権利情報 | © 2011 Bentham Science Publishers Ltd. | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Current Vascular Pharmacology, 9(1), pp.87-98; 2011 |